S&P 500   3,640.47
DOW   29,225.61
QQQ   271.87
Yes, You Can Negotiate with Franchisors. Here's How.
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
2 Casino Stocks Worth Taking a Look At
Asian stocks follow Wall St. higher after UK calms markets
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
This Small-Cap Healthcare Name Is Outperforming Its Index
What Cintas Can Teach Investors About This Bear Market?
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
Wall Street drops back to lowest since 2020 as fear returns
UK's Truss defends economic plan that sent pound tumbling
S&P 500   3,640.47
DOW   29,225.61
QQQ   271.87
Yes, You Can Negotiate with Franchisors. Here's How.
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
2 Casino Stocks Worth Taking a Look At
Asian stocks follow Wall St. higher after UK calms markets
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
This Small-Cap Healthcare Name Is Outperforming Its Index
What Cintas Can Teach Investors About This Bear Market?
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
Wall Street drops back to lowest since 2020 as fear returns
UK's Truss defends economic plan that sent pound tumbling
S&P 500   3,640.47
DOW   29,225.61
QQQ   271.87
Yes, You Can Negotiate with Franchisors. Here's How.
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
2 Casino Stocks Worth Taking a Look At
Asian stocks follow Wall St. higher after UK calms markets
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
This Small-Cap Healthcare Name Is Outperforming Its Index
What Cintas Can Teach Investors About This Bear Market?
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
Wall Street drops back to lowest since 2020 as fear returns
UK's Truss defends economic plan that sent pound tumbling
S&P 500   3,640.47
DOW   29,225.61
QQQ   271.87
Yes, You Can Negotiate with Franchisors. Here's How.
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
2 Casino Stocks Worth Taking a Look At
Asian stocks follow Wall St. higher after UK calms markets
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
This Small-Cap Healthcare Name Is Outperforming Its Index
What Cintas Can Teach Investors About This Bear Market?
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
Wall Street drops back to lowest since 2020 as fear returns
UK's Truss defends economic plan that sent pound tumbling
NASDAQ:TECH

Bio-Techne - TECH Stock Forecast, Price & News

$285.63
-4.02 (-1.39%)
(As of 09/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$282.34
$287.77
50-Day Range
$282.54
$391.85
52-Week Range
$281.42
$531.80
Volume
220,703 shs
Average Volume
249,111 shs
Market Capitalization
$11.20 billion
P/E Ratio
43.15
Dividend Yield
0.44%
Price Target
$475.00

Bio-Techne MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
66.3% Upside
$475.00 Price Target
Short Interest
Healthy
1.81% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.61
Upright™ Environmental Score
News Sentiment
0.22mentions of Bio-Techne in the last 14 days
Based on 23 Articles This Week
Insider Trading
Selling Shares
$751,203 Sold Last Quarter
Proj. Earnings Growth
24.84%
From $7.73 to $9.65 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.99 out of 5 stars

Medical Sector

28th out of 1,097 stocks

Biological Products, Except Diagnostic Industry

3rd out of 172 stocks

TECH stock logo

About Bio-Techne (NASDAQ:TECH) Stock

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Receive TECH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

TECH Stock News Headlines

Bio-Techne (NASDAQ:TECH) Reaches New 12-Month Low at $282.21
Key Price Levels to Watch on the Downside - Yahoo Finance
Alternative Assets Boost Interactive Brokers - Yahoo Finance
AlarmCom- Smart Homes and Security - Yahoo Finance
BIO-TECHNE ISSUES 2022 CORPORATE SUSTAINABILITY REPORT
Bio-Techne paid CEO Charles Kummeth $15.4 million last year
Bio-Techne Corporation: Dropping Coverage of Bio-Techne
See More Headlines
Receive TECH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

TECH Company Calendar

Last Earnings
8/04/2022
Ex-Dividend for 8/29 Dividend
8/12/2022
Dividend Payable
8/29/2022
Today
9/29/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:TECH
CUSIP
87837710
Employees
3,000
Year Founded
1981

Price Target and Rating

Average Stock Price Forecast
$475.00
High Stock Price Forecast
$575.00
Low Stock Price Forecast
$360.00
Forecasted Upside/Downside
+66.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$272.05 million
Pretax Margin
27.26%

Debt

Sales & Book Value

Annual Sales
$1.11 billion
Cash Flow
$10.00 per share
Book Value
$43.36 per share

Miscellaneous

Free Float
37,478,000
Market Cap
$11.20 billion
Optionable
Optionable
Beta
1.25

Social Links


Key Executives

  • Mr. Charles R. KummethMr. Charles R. Kummeth (Age 62)
    CEO, Pres & Director
    Comp: $4.69M
  • Mr. James T. HippelMr. James T. Hippel (Age 51)
    Exec. VP of Fin. & CFO
    Comp: $1.71M
  • Ms. Brenda S. Furlow J.D.Ms. Brenda S. Furlow J.D. (Age 64)
    Exec. VP, Gen. Counsel, Sec. & Chief Compliance Officer
    Comp: $1.27M
  • Mr. Kim  KeldermanMr. Kim Kelderman (Age 55)
    Pres of Diagnostics & Genomics
    Comp: $1.45M
  • David Clair
    Sr. Director of Investor Relations & Corp. Devel.
  • Mr. Gerry Andros
    VP of Sales and Marketing
  • Mr. Robert M. Gavin (Age 54)
    VP of Corp. Devel.
  • Ms. Brenda S. Everson
    Sr. VP & Chief HR Officer
  • Mr. Luca Cicchetti
    Managing Director
  • Mr. Kevin Smyth
    Sr. VP & Chief Digital Officer













TECH Stock - Frequently Asked Questions

Should I buy or sell Bio-Techne stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TECH shares.
View TECH analyst ratings
or view top-rated stocks.

What is Bio-Techne's stock price forecast for 2022?

5 Wall Street analysts have issued twelve-month price targets for Bio-Techne's shares. Their TECH share price forecasts range from $360.00 to $575.00. On average, they predict the company's stock price to reach $475.00 in the next year. This suggests a possible upside of 66.3% from the stock's current price.
View analysts price targets for TECH
or view top-rated stocks among Wall Street analysts.

How have TECH shares performed in 2022?

Bio-Techne's stock was trading at $517.34 at the start of the year. Since then, TECH shares have decreased by 44.8% and is now trading at $285.63.
View the best growth stocks for 2022 here
.

When is Bio-Techne's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our TECH earnings forecast
.

How were Bio-Techne's earnings last quarter?

Bio-Techne Co. (NASDAQ:TECH) announced its quarterly earnings data on Thursday, August, 4th. The biotechnology company reported $2.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.08 by $0.03. The biotechnology company had revenue of $288.30 million for the quarter, compared to analysts' expectations of $287.04 million. Bio-Techne had a net margin of 24.61% and a trailing twelve-month return on equity of 16.97%. The business's quarterly revenue was up 11.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.67 EPS.

How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?

Bio-Techne declared a quarterly dividend on Friday, August 5th. Investors of record on Monday, August 15th will be paid a dividend of $0.32 per share on Monday, August 29th. This represents a $1.28 annualized dividend and a dividend yield of 0.45%. The ex-dividend date is Friday, August 12th.
Read our dividend analysis for TECH
.

Is Bio-Techne a good dividend stock?

Bio-Techne (NASDAQ:TECH) pays an annual dividend of $1.28 per share and currently has a dividend yield of 0.44%. The dividend payout ratio is 19.34%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TECH will have a dividend payout ratio of 13.26% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for TECH.

What is Charles Kummeth's approval rating as Bio-Techne's CEO?

95 employees have rated Bio-Techne Chief Executive Officer Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Bio-Techne own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and Boeing (BA).

What is Bio-Techne's stock symbol?

Bio-Techne trades on the NASDAQ under the ticker symbol "TECH."

How do I buy shares of Bio-Techne?

Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Techne's stock price today?

One share of TECH stock can currently be purchased for approximately $285.63.

How much money does Bio-Techne make?

Bio-Techne (NASDAQ:TECH) has a market capitalization of $11.20 billion and generates $1.11 billion in revenue each year. The biotechnology company earns $272.05 million in net income (profit) each year or $6.62 on an earnings per share basis.

How many employees does Bio-Techne have?

The company employs 3,000 workers across the globe.

Does Bio-Techne have any subsidiaries?
The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., Cliniqa, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences.
Read More
How can I contact Bio-Techne?

Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The official website for the company is www.bio-techne.com. The biotechnology company can be reached via phone at (612) 379-8854, via email at ir@bio-techne.com, or via fax at 612-656-4400.

This page (NASDAQ:TECH) was last updated on 9/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.